Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Last trade$6.33
Day change-$0.15 (-2.31%)
Day range$6.11 – $6.61
Volume625,905
Market cap$723M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$723.24M
Price / earnings
—
Price / book
2.11×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.71×
Profitability
Earnings per share
-$1.93
Return on assets
-55.21%
Return on equity
-62.92%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
11.99×
Quick ratio
11.99×
Cash ratio
4.14×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$200.3M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SLDB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$14.06M
$13.12M
$11.17M
$11.27M
$9.2M
$9.28M
$9.14M
$9.13M
Research and development
$43.6M
$44.27M
$46.14M
$38.14M
$38.86M
$32.42M
$30.91M
$30.77M
Total operating expenses
$57.66M
$57.38M
$57.31M
$49.4M
$48.06M
$41.69M
$40.05M
$39.9M
Operating income
-$57.66M
-$57.38M
-$57.31M
-$49.4M
-$48.06M
-$41.69M
-$40.05M
-$39.9M
Interest expense
$0
$0
$0
-$5K
$336K
-$60K
-$68K
-$75K
Income before taxes
-$53.95M
-$54.8M
-$56.74M
-$49.79M
-$45.78M
-$39.48M
-$39.28M
-$42.6M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$53.95M
-$54.8M
-$56.74M
-$49.79M
-$45.78M
-$39.48M
-$39.28M
-$42.6M
Net income attributable to common shareholders
-$53.95M
-$54.8M
-$56.74M
-$49.79M
-$45.78M
-$39.48M
-$39.28M
-$42.6M
EBITDA
-$57.24M
-$56.99M
-$56.91M
-$48.94M
-$47.68M
-$41.31M
-$39.65M
-$39.41M
Basic earnings per share
-$0.36
-$0.38
-$0.52
-$0.52
-$0.48
-$0.42
-$0.59
-$1.00
Diluted earnings per share
-$0.36
-$0.38
-$0.52
-$0.52
-$0.48
-$0.42
-$0.59
-$1.00
Recent news
Company coverage with links to the original publishers.
DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.
U.S. Department of Health and Human Services added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel, which is expected to accelerate early detection and improve patient outcomes.
Solid Biosciences received FDA Rare Pediatric Disease designation for SGT-212, a dual-route gene therapy targeting Friedreich's ataxia. The therapy aims to restore frataxin protein levels and address neurologic, cardiac, and systemic disease manifestations.
Solid Biosciences has signed a non-exclusive worldwide license agreement with Andelyn Biosciences to provide access to its proprietary AAV-SLB101 gene therapy capsid, expanding collaborative efforts to over 30 agreements.
Solid Biosciences will participate in two healthcare investor conferences in November and December 2025, featuring presentations by its President/CEO and Chief Medical Officer, with live webcasts available.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.